Is there a role for direct renin inhibitors in chronic kidney disease?

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 5, 2009, Pages 397-403

  Peixoto, Aldo J ^a,b   Orias, Marcelo ^c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sanatorio Allende   (Argentina)

^d INSTITUTO DE INVESTIGACIÓN MÉDICA MERCEDES Y MARTÍN FERREYRA   (Argentina)

Author keywords

Albuminuria; Aliskiren; Chronic kidney disease; Hypertension; Renin inhibitor

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPITHELIAL SODIUM CHANNEL; EPLERENONE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PRORENIN RECEPTOR; RENIN INHIBITOR; SPIRONOLACTONE; VALSARTAN;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL;

ANTIHYPERTENSIVE AGENTS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 69549112964     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832e3183     Document Type: Review

References (36)

1. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3:486-492.
2. Brown MJ. Aliskiren. Circulation 2008; 118:773-784.
3. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76:23-31.
4. Dockery BK, Bisognano JD. Direct renin inhibition: an analysis of possible benefits. Curr Hypertens Rep 2008; 10:313-318.
5. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368:1449-1456.
6. Stanton A. Now that we have a direct renin inhibitor, what should we do with it? Curr Hypertens Rep 2008; 10:194-200.
7. Berl T. Renal protection by inhibition of the renin-angiotensin- aldosterone system [review]. J Renin Angiotensin Aldosterone Syst 2009; 10:1-8.
8. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1:221-228.
9. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46:569-576. (Pubitemid 41376839)
10. Feldt S, Maschke U, Dechend R, et al. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008; 19:743-748.
11. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50:2398-2404. (Pubitemid 47512400)
12. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52:130-136. Aliskiren decreases renal injury and renal transforming growth factor-b expression in dTGR.
13. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens 2009. [Epub ahead of print] Aliskiren decreases renal injury and renal transforming growth factor-b expression in dTGR.
14. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9:163-175.
15. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119:417-425. Aliskiren provides effective long-term BP control in essential hypertension.
16. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221-229. (Pubitemid 47069535)
17. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11-20. (Pubitemid 46014059)
18. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8:190-198. (Pubitemid 351166266)
19. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49:276-284. (Pubitemid 46143002)
20. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22:112-121. Reanalysis of published literature suggesting that aliskiren is not effective in low-renin hypertension.
21. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24:243-256.
22. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. Aliskiren decreases proteinuria when added to losartan in patients with early diabetic nephropathy. (Pubitemid 351793017)
23. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73:1419-1425. Aliskiren results in antiproteinuric effects beyond its BP-lowering properties in patients with diabetic nephropathy. (Pubitemid 351770494)
24. Fisher ND, Allan D, Kifor I, et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 1994; 23:44-51.
25. Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
26. Hollenberg NK, Price DA, Fisher ND, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63:172-178. (Pubitemid 35463918)
27. Frandsen E, Persson F, Boomsma F, et al. The effects of renin inhibition alone or in combination with angiotensin 2 receptor blockade on markers of the renin-angiotensin system. Diabetologia 2008; 51 (Suppl 1):491-492.
28. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24:1663-1671. Description and proposed analyses for this forthcoming landmark study.
29. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46:1309-1315. (Pubitemid 43189728)
30. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Failure 2008; 1:17-24.
31. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537. Aliskiren is equivalent to losartan in left ventricular hypertrophy reduction in hypertension. Combination therapy does not provide additive effects.
32. Danser AH. (Pro)renin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens 2009; 18:74-78.
33. Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18:1789-1795. (Pubitemid 46870315)
34. Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51:682-688. (Pubitemid 351301521)
35. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123. (Pubitemid 44871374)
36. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52:486-493.